BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 23045585)

  • 21. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte.
    Casasnovas RO; Mounier N; Brice P; Divine M; Morschhauser F; Gabarre J; Blay JY; Voillat L; Lederlin P; Stamatoullas A; Bienvenu J; Guiguet M; Intrator L; Grandjean M; Brière J; Ferme C; Salles G;
    J Clin Oncol; 2007 May; 25(13):1732-40. PubMed ID: 17389336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma.
    Schlette EJ; Medeiros LJ; Goy A; Lai R; Rassidakis GZ
    J Clin Oncol; 2004 May; 22(9):1682-8. PubMed ID: 15117990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. The Groupe d'Etude des Lymphomes de l'Adulte.
    Diviné M; Lepage E; Brière J; Pautier P; Dupriez B; Lederlin P; Mineur P; Tilly H; Blanc M; Audhuy B; Herbrecht R; Coiffier B; Reyes F
    J Clin Oncol; 1996 Jan; 14(1):240-8. PubMed ID: 8558204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical analysis of primary systemic anaplastic large cell lymphoma: a report of 57 cases.
    Wang FH; Li YH; Zeng J; Rao HL; Xia ZJ; Sun XF; Huang HQ; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2009 Jan; 28(1):49-53. PubMed ID: 19448428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy of therapy of different variants of anaplastic large T-cell lymphomas].
    Vinogradova IuE; Lutsenko IN; Kaplanskaia IB; Vorob'ev IA; Samoĭlova RS; Gorgidze LA; Ryzhikova NA; Valiev TT; Giliazitdinova EA; Dzhulakian UL; Egorova EK; Zvonkov EE; Krasil'nikova BB; Magomedova AU; Margolin OV; Mar'in DS; Kremenetskaia AM; Kravchenko SK; Vorob'ev AI
    Ter Arkh; 2008; 80(7):33-7. PubMed ID: 18763592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas.
    Salaverria I; Beà S; Lopez-Guillermo A; Lespinet V; Pinyol M; Burkhardt B; Lamant L; Zettl A; Horsman D; Gascoyne R; Ott G; Siebert R; Delsol G; Campo E
    Br J Haematol; 2008 Mar; 140(5):516-26. PubMed ID: 18275429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
    Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
    Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multivariate analysis of the survival of patients with aggressive lymphoma: variations in the predictive value of prognostic factors during the course of the disease. Groupe d'Etudes des Lymphomes de l'Adulte.
    Mounier N; Morel P; Haioun C; Coiffier B; Tilly H; Chatelain C; Lederlin P; Thyss A; Herbrecht R; Gisselbrecht C; Lepage E
    Cancer; 1998 May; 82(10):1952-62. PubMed ID: 9587130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients--a study of the groupe d'Etude des lymphomes de l'Adulte.
    Decaudin D; Lepage E; Brousse N; Brice P; Harousseau JL; Belhadj K; Tilly H; Michaux L; Chèze S; Coiffier B; Solal-Céligny P
    J Clin Oncol; 1999 Aug; 17(8):2499-505. PubMed ID: 10561315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis.
    Mussolin L; Damm-Welk C; Pillon M; Zimmermann M; Franceschetto G; Pulford K; Reiter A; Rosolen A; Woessmann W
    Leukemia; 2013 Feb; 27(2):416-22. PubMed ID: 22907048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
    Mounier N; Gisselbrecht C; Brière J; Haioun C; Feugier P; Offner F; Recher C; Stamatoullas A; Morschhauser F; Macro M; Thieblemont C; Sonet A; Fabiani B; Reyes F;
    Ann Oncol; 2004 Dec; 15(12):1790-7. PubMed ID: 15550584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognosis of patients with advanced Hodgkin's disease: evaluation of four prognostic models using 344 patients included in the Group d'Etudes des Lymphomes de l'Adulte Study.
    Fermé C; Bastion Y; Brice P; Lederlin P; Diviné M; Gabarre J; Assouline D; Ferrant A; Berger F; Lepage E
    Cancer; 1997 Sep; 80(6):1124-33. PubMed ID: 9305714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of p80 and visceral involvement in childhood CD30 anaplastic large cell lymphoma (ALCL).
    Massimino M; Spreafico F; Luksch R; Giardini R
    Med Pediatr Oncol; 2001 Aug; 37(2):97-102. PubMed ID: 11496346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage.
    Rassidakis GZ; Sarris AH; Herling M; Ford RJ; Cabanillas F; McDonnell TJ; Medeiros LJ
    Am J Pathol; 2001 Aug; 159(2):527-35. PubMed ID: 11485911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic anaplastic large-cell lymphoma: results from the non-Hodgkin's lymphoma classification project.
    Weisenburger DD; Anderson JR; Diebold J; Gascoyne RD; MacLennan KA; Müller-Hermelink HK; Nathwani BN; Ullrich F; Armitage JO
    Am J Hematol; 2001 Jul; 67(3):172-8. PubMed ID: 11391714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secondary ALK negative anaplastic large cell lymphoma in a patient with lymphomatoid papulosis of 40 years duration.
    Marschalkó M; Eros N; Holló P; Hársing J; Bottlik G; Bátai A; Csukly Z; Masszi T; Szentirmai Z; Fodor J; Kárpáti S; Matolcsy A; Csomor J
    Am J Dermatopathol; 2010 Oct; 32(7):708-12. PubMed ID: 20644462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anaplastic large cell lymphoma in leukemic phase: extraordinarily high white blood cell count.
    Nguyen JT; Condron MR; Nguyen ND; De J; Medeiros LJ; Padula A
    Pathol Int; 2009 May; 59(5):345-53. PubMed ID: 19432678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and laboratory characteristics of systemic anaplastic large cell lymphoma in Chinese patients.
    Wang YF; Yang YL; Gao ZF; Zhou CJ; Gregg X; Shi YF; Wang J; Yang XF; Ke XY
    J Hematol Oncol; 2012 Jul; 5():38. PubMed ID: 22769020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of seven biological factors (Hsp90a, p53, MDM2, Bcl-2, Bax, Cytochrome C, and Cleaved caspase3) with clinical outcomes of ALK+ anaplastic large-cell lymphoma.
    Li HL; Huang XP; Zhou XH; Ji TH; Wu ZQ; Wang ZQ; Jiang HY; Liu FR; Zhao T
    Biomed Environ Sci; 2011 Dec; 24(6):630-41. PubMed ID: 22365399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma.
    Gascoyne RD; Aoun P; Wu D; Chhanabhai M; Skinnider BF; Greiner TC; Morris SW; Connors JM; Vose JM; Viswanatha DS; Coldman A; Weisenburger DD
    Blood; 1999 Jun; 93(11):3913-21. PubMed ID: 10339500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.